3349 — Cosmos Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedLarge CapNeutral

Annual income statement for Cosmos Pharmaceutical, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.

	2019 May 31st	2020 May 31st	2021 May 31st	2022 May 31st	2023 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	611,137	684,403	726,424	755,414	827,697
Cost of Revenue
Gross Profit	121,784	134,984	145,111	151,448	168,718
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	586,516	656,470	694,706	725,696	797,882
Operating Profit	24,621	27,933	31,718	29,718	29,815
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	27,139	30,402	38,596	33,048	32,773
Provision for Income Taxes
Net Income After Taxes	19,185	21,435	27,157	23,156	23,798
Net Income Before Extraordinary Items
Net Income	19,185	21,435	27,157	23,156	23,798
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	19,185	21,435	27,156	23,155	23,797
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	487	562	637	581	607
Dividends per Share